CluenexInsmed INSM
Insmed scores weak on business quality (4.3 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Insmed does
Insmed sells specialized therapeutics for rare pulmonary conditions, generating revenue primarily from commercial drug sales to patients through specialty pharmacies. The company is aggressively scaling its commercial and clinical pipeline to expand its addressable rare disease market footprint.
- What it does best
Insmed dominates niche pulmonary therapeutics, posting a gross margin of 83.4% that easily outpaces peer BIIB at 74.0%. This high margin reflects specialized pricing power and complex manufacturing barriers that block generic entrants.
- The main risk
Heavy cash burn remains a severe vulnerability, with free cash flow sitting at -$808.0M and an operating margin of -73.9%. Continued losses threaten capital reserves unless top-line expansion rapidly outpaces clinical and SG&A expenses.
Quality, check by check
Scored against its own industry, from company filings.
Operating margins sit deeply negative at -73.9% alongside a -76.8% net margin, driven by immense R&D and commercial spend that prevents profitability despite strong gross margins.
IP protection locks in rare disease patients and prescribers, backed by an 83.4% gross margin ranking in the top quartile of its sector, though wide net losses limit structural durability.
Revenue growth surges at 66.5% over the prior period, placing the company in the top decile of its sector at the 98th percentile and accelerating rapidly from historical levels.
Total debt of $728.0M against $1.4B in cash provides a net cash cushion of $702.0M, but negative free cash flow of -$808.0M burns capital fast, weakening the balance sheet profile.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
3 sold $35.7M outside pre-planned sales.
Our sealed record on INSM
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Insmed scores weak on the Cluenex quality check (4.3 of 10), measured against its own industry. Profitability is weak, moat weak, growth fast and financial health weak.
In the last 90 days of SEC Form 4 filings: 3 sold $35.7M outside pre-planned sales.
Oct 28, 2026.
See INSM today
- Today's verdict on INSM, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Insmed (INSM)”, https://cluenex.com/stocks/insm/, data as of Oct 10, 2026.